Your browser doesn't support javascript.
mRNA COVID-19 vaccine effectiveness against SARS-CoV-2 infection in a prospective community cohort, rural Wisconsin, November 2020 to December 2021.
McLean, Huong Q; McClure, David L; King, Jennifer P; Meece, Jennifer K; Pattinson, David; Neumann, Gabriele; Kawaoka, Yoshihiro; Rolfes, Melissa A; Belongia, Edward A.
  • McLean HQ; Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA.
  • McClure DL; Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA.
  • King JP; Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA.
  • Meece JK; Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA.
  • Pattinson D; Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, Wisconsin, USA.
  • Neumann G; Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, Wisconsin, USA.
  • Kawaoka Y; Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, Wisconsin, USA.
  • Rolfes MA; Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Belongia EA; Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA.
Influenza Other Respir Viruses ; 16(4): 607-612, 2022 07.
Article in English | MEDLINE | ID: covidwho-1703642
ABSTRACT
Reduced COVID-19 vaccine effectiveness (VE) has been observed with increasing predominance of SARS-CoV-2 Delta (B.1.617.2) variant. Two-dose VE against laboratory-confirmed SARS-CoV-2 infection (symptomatic and asymptomatic) was estimated using Cox proportional hazards models with time-varying vaccination status in a prospective rural community cohort of 1266 participants aged ≥12 years. Between November 3, 2020 and December 7, 2021, VE was 56% for mRNA COVID-19 vaccines overall, 65% for Moderna, and 50% for Pfizer-BioNTech. VE when Delta predominated (June to December 2021) was 54% for mRNA COVID-19 vaccines overall, 59% for Moderna, and 52% for Pfizer-BioNTech.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines / Variants Limits: Humans Country/Region as subject: North America Language: English Journal: Influenza Other Respir Viruses Journal subject: Virology Year: 2022 Document Type: Article Affiliation country: Irv.12970

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines / Variants Limits: Humans Country/Region as subject: North America Language: English Journal: Influenza Other Respir Viruses Journal subject: Virology Year: 2022 Document Type: Article Affiliation country: Irv.12970